Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 23, 2020 9:51am
138 Views
Post# 32168372

RE:RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"

RE:RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"CYDY last October had SP 35 cents, they believed their drug could be a candidate for both HIV MDR and NASH so they went out and heavily promote their prospects, the SP in the matter of a couple of months increased some %300 to %400, they also acted fast and started the regulatory process, then they believed their drug can be used for covid19 so they did the same exercise and start the process fast for that program followed by heavy promotional efforts targeting the retail investors they had a all time high SP at $10 this year and yes you heard it right from 35 cents to $10 US  in less than a year! they then completed a couple of rounds of convertibles at $10 so now they are well funded(I believe their valuation was too volatile to dilute)
They went on well recognized social media platforms like drbeen(YouTube), every time they add a couple of patients to any of their programs  there was a PR so they were constantly trying to get the attention of the retail investors and yes they succeeded, just go and look at their yahoo bullboard,articles on seeking alpha and motley fool commentary sections etc etc and you see they are followed by hundreds or even thousands of Intrested folks.
They didn't just talk the talk they also walked the walk, their programs are up and running and it all happened in a little more than one year.
Now of course they are crooked law firms out there trying to make money from chasing traffic tickets to going after well funded companies and yes there might be some law suits and yes there are well organized large short sellers targeting any company when the opportunity arise and that is part of a game which has been played for decades.
Now last October Thera has a SP $4 Canadian they also believed their drugs can treat cancer and HIV  NASH, more than a year later even they shifted from HIV to general NASH they still believe their drugs have promising prospects but where is the execution followed by promotional efforts.
That is why CYDY has a market cap of $4 billion vs THTX $170 million....



Wino115 wrote: As SPCEO has pointed out, the market is unfortunately very highly swayed in the very short term by the trading around set algorithms, some, for example, based around things like the silliness of counting the number of positive vs. negative words in a PR announcement, any "new buy" announced (like we saw today), anything having to do with certain types of announcements (like the AACR presentation day when THTX  traded 7mil shares, mostly traded amongst themselves), etc....  I would not expect this "Loe's Bounce" to have legs. It's all noise trading, not investing.  

By the way, this is also why some companies are constantly announcing stuff -- to feed the day traders and algos. It can stay that way until it can't -- until one of the short selling publishers brings some sense to it like Citron did to CYDY.  Unfortunately it can last long enough to create $4bil of value in CYDY based on a drug that so far hasn't shown it can do anything.  

Let's just hope that THTX can have actual legitimate news to disseminate on a regular basis starting around now and going through the year to create the momentum it needs -- financial momentum around revenues/cash flows, share price momentum, pipeline momentum and newsflow momentum.  They need it in all realms!



Jasonthehumble wrote: Your theory might be true due to the high volume compared to the average volume.




<< Previous
Bullboard Posts
Next >>